XEN1101 is named as a drug or biological intervention in 3 clinical trials in our UK, USA and Ireland trial registers, 1 of which is recruiting. The lead sponsor is Xenon Pharmaceuticals Inc.. Registered phases: Phase 3 and Phase 2. Conditions studied include Focal Epilepsy; Tonic-Clonic Seizures; Primary Generalized Tonic-Clonic Seizures.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05667142 | A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures (ClinicalTrials.gov ↗) Primary Generalized Tonic-Clonic Seizures |
Phase 3 | Recruiting |
| NCT05718817 | An Open-label Study of XEN1101 in Epilepsy Focal Epilepsy, Tonic-Clonic Seizures |
Phase 3 | By invitation |
| NCT03796962 | A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy (ClinicalTrials.gov ↗) Focal Epilepsy |
Phase 2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Focal Epilepsy | 2 |
| Tonic-Clonic Seizures | 1 |
| Primary Generalized Tonic-Clonic Seizures | 1 |
| Lead sponsor | Trials |
|---|---|
| Xenon Pharmaceuticals Inc. | 3 |
| Register | XEN1101 trials |
|---|---|
| Clinical trials in UK | 3 |
| Clinical trials in USA | 3 |
| Clinical trials in Ireland | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how XEN1101 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists XEN1101 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.